Dihexa: Legal Status and the Missing Human Data

Dihexa is marketed online for memory, focus and brain repair. Of all the peptides FDA has listed in its compounding reviews, it is one with the least human information: FDA says it found none.

Legal status of Dihexa

Under FDA review

Dihexa is waiting for an FDA advisory committee review planned before the end of February 2027 ^{[12] [4]}. Until FDA acts, it cannot be legally compounded ^[7].

FDA status

FDA removed it from Category 2 in April 2026 because the nominators withdrew their nominations ^[6]. That removal did not make it legal to compound ^[7]. FDA now lists it as "nominated but withdrawn," which is outside every category ^[2]. It is not in Category 1 and is not on the 503A bulks list, so a 503A pharmacy may not lawfully compound it today ^[1]. FDA says it has not found any human exposure data for dihexa acetate ^[2].

Advisory committee

Not yet reviewed. It is one of five peptides FDA plans to bring to the committee: GHK-Cu, LL-37, dihexa, Melanotan II and PEG-MGF ^[12]. That review is expected before the end of February 2027 ^{[12] [4]}. No date had been set as of Oct 16, 2026 ^[4].

FDA-approved products

None. We found no FDA-approved drug that contains Dihexa.

Sports (WADA)

Dihexa is not named on the 2026 list ^[9]. The list's S0 class covers substances with no approval by any government health authority for human use ^[9]. Whether that class covers Dihexa is a judgment call, so athletes should ask their anti-doping agency before use.

What happens next

FDA plans to bring it to its Pharmacy Compounding Advisory Committee before the end of February 2027, according to law firm reports ^{[12] [4]}. No meeting date had been set as of Oct 16, 2026 ^[4]. Even a favorable vote would not be binding. FDA would still have to act through rulemaking or another formal step ^[10].

Checked against FDA sources on Oct 24, 2026. We update this box when FDA acts. Report a change: [email protected].

Dihexa and FDA, step by step

• Sept 29, 2023: FDA placed dihexa acetate in Category 2, substances with significant safety risks ^[5].
• April 15, 2026: FDA announced it would remove 12 peptides, including dihexa, from Category 2 because the nominators withdrew ^[6].
• Late April 2026: FDA's safety page now lists dihexa acetate as nominated but withdrawn, a status that does not allow compounding ^{[2] [7]}.
• Before the end of February 2027: FDA plans an advisory committee meeting on dihexa acetate and four other substances ^[3].

Today, dihexa fails every test a 503A pharmacy must meet: no USP or NF monograph, not in an approved drug, not on the bulks list, not in Category 1 ^{[8] [1]}. A prescription does not fix that.

What dihexa is sold as

FDA lists it as dihexa acetate ^[2]. Online sellers market it for memory and focus. FDA has not published a briefing on dihexa yet, so there is no FDA summary of how it works or what animal studies show. We did not find a primary source we could cite for its mechanism, so we do not describe one here. FDA's briefing for the 2027 meeting should fill that gap, and we will add it.

Zero human data: what that means for you

FDA's statement is blunt: it "has not identified any human exposure data on drug products containing dihexa acetate" ^[2]. That means:

• No published study tells you what a safe amount is, or whether any amount is safe ^[2].
• No study reports side effect rates, drug interactions or long-term effects.
• No regulator has checked what is in a product sold as dihexa.

Dihexa and drug testing

Dihexa does not appear on the 2026 WADA list ^[9]. Athletes should not read that as permission: S0 is written to cover active substances without government approval for human therapy, named or not ^[9]. A ruling from your anti-doping body is the only safe answer.

What the 2027 review could change

FDA's meeting page says the time and place for the next meeting "will be scheduled in the coming months" ^[3]. If the committee votes in favor, the vote is still advice; FDA would need a proposed rule, a Category 1 listing or enforcement discretion before any pharmacy could use dihexa ^[10]. If FDA staff follow the approach they took for the July 2026 peptides, the briefing documents will be posted before the meeting, and they will be the first public FDA review of dihexa's evidence.

Legal access today

"Research use only" products are not a legal route for personal use ^[11]. See our peptide FDA status tracker, the other 2027 candidates LL-37 and GHK-Cu, Semax for another peptide marketed for the brain, BPC-157, the legal peptide price tracker and our longevity guide.

Dihexa status history

• Apr 22, 2026: The removal took effect around this date. FDA now lists it as nominated but withdrawn, which does not allow compounding ^{[2] [7]}.
• Apr 21, 2026: A law firm report said the advisory committee will meet before the end of February 2027 to review it and four other peptides ^[12].
• Apr 15, 2026: FDA gave seven days' notice that it would remove 12 peptides, including this one, from Category 2 because the nominators withdrew ^[6].
• Sep 29, 2023: FDA placed it in Category 2, citing significant safety risks ^[5].

The other substances on FDA's February 2027 review list with their own pages: GHK-Cu, LL-37 and Melanotan II. Already voted on in July 2026: TB-500 and KPV.

How we check

There is less to check on dihexa than on most peptides, which is part of the story. Our Oct 24, 2026 pass covered FDA's safety-risk entry, which carries the no-human-data statement, plus the categories document and the 2027 meeting notice ^{[2] [1] [3]}. When FDA posts a briefing, we will summarize it here. More: editorial standards.